Drug-induced heart failure

被引:77
作者
Feenstra, J
Grobbee, DE
Remme, WJ
Stricker, BHC
机构
[1] Erasmus Univ, Dept Epidemiol & Biostat, Sch Med, Pharmacoepidemiol Unit, NL-3000 DR Rotterdam, Netherlands
[2] Drug Safety Unit, Inspectorate Hlth Care, The Hague, Netherlands
[3] Univ Utrecht, Sch Med, Julius Ctr Patient Oriented Res, Utrecht, Netherlands
[4] STICARES, Cardiovasc Res Fdn, Rotterdam, Netherlands
关键词
D O I
10.1016/S0735-1097(99)00006-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure is a clinical syndrome that is predominantly caused by cardiovascular disorders such as coronary heart disease and hypertension. However, several classes of drugs may induce heart failure in patients without concurrent cardiovascular disease or may precipitate the occurrence of heart failure in patients with preexisting left ventricular impairment. We reviewed the literature on drug-induced heart failure, using the MEDLINE database and lateral references. Successively, we discuss the potential role in the occurrence of heart failure of cytostatics, immunomodulating drugs, antidepressants, calcium channel blocking agents, nonsteroidal anti-inflammatory drugs, antiarrhythmics, beta-adrenoceptor blocking agents, anesthetics and some miscellaneous agents. Drug-induced heart failure may play a role in only a minority of the patients presenting with heart failure. Nevertheless, drug-induced heart failure should be regarded as a potentially preventable cause of heart failure, although sometimes other priorities do not offer therapeutic alternatives (e.g., anthracycline-induced cardiomyopathy). The awareness of clinicians of potential adverse effects on cardiac performance by several classes of drugs, particularly in patients with preexisting ventricular dysfunction, may contribute to timely diagnosis and prevention of drug-induced heart failure. (C) 1999 by the American College of Cardiology.
引用
收藏
页码:1152 / 1162
页数:11
相关论文
共 134 条
[1]  
AABO K, 1987, LANCET, V2, P637
[2]   5-fluorouracil-induced severe but reversible cardiogenic shock: A case report [J].
Akhtar, SS ;
Wani, BA ;
Bano, ZA ;
Salim, KP ;
Handoo, FA .
TUMORI, 1996, 82 (05) :505-507
[3]  
ARONOFF GR, 1992, J RHEUMATOL, V19, P25
[4]   CARDIOVASCULAR EFFECTS OF TOPICAL BETA-BLOCKERS DURING EXERCISE [J].
ATKINS, JM ;
PUGH, BR ;
TIMEWELL, RM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1985, 99 (02) :173-175
[5]   CYCLOPHOSPHAMIDE PHARMACOKINETICS - CORRELATION WITH CARDIAC TOXICITY AND TUMOR RESPONSE [J].
AYASH, LJ ;
WRIGHT, JE ;
TRETYAKOV, O ;
GONIN, R ;
ELIAS, A ;
WHEELER, C ;
EDER, JP ;
ROSOWSKY, A ;
ANTMAN, K ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :995-1000
[6]  
BALL S, 1987, ARCH OPHTHALMOL-CHIC, V105, P320
[7]  
Baselga J, 1998, CANCER RES, V58, P2825
[8]   ASSESSMENT OF SYSTEMIC EFFECTS OF DIFFERENT OPHTHALMIC BETA-BLOCKERS IN HEALTHY-VOLUNTEERS [J].
BAUER, K ;
BRUNNERFERBER, F ;
DISTLERATH, LM ;
LIPPA, EA ;
BINKOWITZ, B ;
TILL, P ;
KAIK, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (06) :658-664
[9]   CARDIOVASCULAR EFFECTS OF PLASMA-LEVELS OF THIOPENTAL NECESSARY FOR ANESTHESIA [J].
BECKER, KE ;
TONNESEN, AS .
ANESTHESIOLOGY, 1978, 49 (03) :197-200
[10]   TOXICITY OF ORAL IRON CHELATOR L1 [J].
BERDOUKAS, V ;
BENTLEY, P ;
FROST, H ;
SCHNEBLI, HP .
LANCET, 1993, 341 (8852) :1088-1088